Any feedback?
Literature summary for 3.4.14.5 extracted from
- Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes (2006), Curr. Med. Res. Opin., 22, 1939-1947.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | co-administration of the dipeptidyl peptidase-4 inhibitor sitagliptin and metformin is well tolerated in patients with type 2 diabetes and does not alter the steady-state pharmacokinetics of either agent | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| sitagliptin | - |
Homo sapiens |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
